CRANBURY, N.J., May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before the open of the U.S. financial markets.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 15, 2024, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.
Schedule for the Operating Results Press Release, Conference Call / Audio Webcast | |
Q3 Fiscal Year 2024 Results Press Release | 5/15/2024 at 7:30 a.m. ET |
Q3 Fiscal Year 2024 Conference Call-Live | 5/15/2024 at 11:00 a.m. ET |
Q3 Fiscal Year 2024 Conference Call-Replay | 5/15/2024-5/29/2024 |
The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com or by clicking here.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
Last Trade: | US$1.20 |
Daily Change: | -0.01 -1.16 |
Daily Volume: | 148,491 |
Market Cap: | US$28.060M |
December 19, 2024 December 16, 2024 November 25, 2024 November 14, 2024 November 04, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load